Blueprint Historical Income Statement
| BPMC Stock | USD 85.18 2.07 2.37% |
Historical analysis of Blueprint Medicines income statement accounts such as Interest Expense of 54.2 M, Selling General Administrative of 293.8 M or Other Operating Expenses of 390 M can show how well Blueprint Medicines Corp performed in making a profits. Evaluating Blueprint Medicines income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Blueprint Medicines's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Blueprint Medicines Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Blueprint Medicines Corp is a good buy for the upcoming year.
Blueprint |
About Blueprint Income Statement Analysis
Blueprint Medicines Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Blueprint Medicines shareholders. The income statement also shows Blueprint investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Blueprint Medicines Income Statement Chart
Blueprint Medicines Corp Income Statement is one of the three primary financial statements used for reporting Blueprint's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Blueprint Medicines Corp revenue and expense. Blueprint Medicines Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Blueprint Medicines' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 293.8 M, whereas Other Operating Expenses is forecasted to decline to about 390 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Blueprint Medicines Corp. It is also known as Blueprint Medicines overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Blueprint Medicines' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At present, Blueprint Medicines' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 293.8 M, whereas Other Operating Expenses is forecasted to decline to about 390 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 7.4M | 16.8M | 51.6M | 54.2M | Depreciation And Amortization | 6.5M | 11.7M | 11.7M | 12.2M |
Blueprint Medicines income statement Correlations
Click cells to compare fundamentals
Blueprint Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Blueprint Medicines income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 5.3M | 6.6M | 6.5M | 11.7M | 11.7M | 12.2M | |
| Interest Expense | 13.7M | 12.8M | 7.4M | 16.8M | 51.6M | 54.2M | |
| Selling General Administrative | 96.4M | 148.3M | 181.8M | 219.3M | 279.8M | 293.8M | |
| Other Operating Expenses | 427.8M | 485.0M | 822.1M | 741.6M | 735.7M | 390.0M | |
| Operating Income | (366.6M) | 302.1M | (648.5M) | (549.3M) | (486.3M) | (462.0M) | |
| Ebit | (366.6M) | 302.1M | (648.5M) | (549.3M) | (486.3M) | (462.0M) | |
| Research Development | 331.5M | 326.9M | 601.0M | 477.4M | 416.1M | 271.9M | |
| Ebitda | (361.3M) | 308.7M | (642.0M) | (537.5M) | (474.6M) | (450.9M) | |
| Total Operating Expenses | 427.8M | 484.6M | 804.1M | 723.7M | 711.2M | 384.0M | |
| Income Before Tax | (347.7M) | 314.9M | (641.1M) | (552.3M) | (506.0M) | (480.7M) | |
| Total Other Income Expense Net | 18.9M | 12.8M | 7.4M | (3.0M) | (19.7M) | (18.8M) | |
| Net Income | (328.7M) | 313.9M | (644.1M) | (557.5M) | (507.0M) | (481.6M) | |
| Income Tax Expense | (19.0M) | 1.1M | 3.0M | 5.2M | 968K | 1.0M | |
| Total Revenue | 66.5M | 793.7M | 180.1M | 204.0M | 249.4M | 175.9M | |
| Gross Profit | 66.5M | 793.3M | 162.1M | 186.2M | 224.9M | 165.7M | |
| Net Income From Continuing Ops | (414.2M) | 313.9M | (644.1M) | (557.5M) | (554.7M) | (527.0M) | |
| Cost Of Revenue | 331.5M | 425K | 17.9M | 17.8M | 24.5M | 23.2M | |
| Net Income Applicable To Common Shares | (347.7M) | 313.9M | (644.1M) | (557.5M) | (501.8M) | (476.7M) | |
| Non Operating Income Net Other | (100K) | (366K) | (1.5M) | 2.0M | 1.8M | 1.4M | |
| Net Interest Income | 13.7M | 6.6M | 2.4M | (16.8M) | (22.9M) | (21.7M) | |
| Reconciled Depreciation | 5.3M | 6.6M | 6.5M | 11.7M | 17.2M | 18.0M |
Blueprint Medicines Investors Sentiment
The influence of Blueprint Medicines' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Blueprint. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Blueprint Medicines' public news can be used to forecast risks associated with an investment in Blueprint. The trend in average sentiment can be used to explain how an investor holding Blueprint can time the market purely based on public headlines and social activities around Blueprint Medicines Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Blueprint Medicines' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Blueprint Medicines' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Blueprint Medicines' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Blueprint Medicines.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Blueprint Medicines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Blueprint Medicines' short interest history, or implied volatility extrapolated from Blueprint Medicines options trading.
Pair Trading with Blueprint Medicines
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Blueprint Medicines position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will appreciate offsetting losses from the drop in the long position's value.Moving together with Blueprint Stock
| 0.86 | ERAS | Erasca Inc Financial Report 20th of May 2024 | PairCorr |
| 0.68 | BMY | Bristol Myers Squibb Financial Report 25th of April 2024 | PairCorr |
Moving against Blueprint Stock
| 0.68 | BIIB | Biogen Inc Financial Report 23rd of April 2024 | PairCorr |
| 0.67 | AMGN | Amgen Inc Financial Report 25th of April 2024 | PairCorr |
| 0.46 | ABVC | ABVC Biopharma | PairCorr |
The ability to find closely correlated positions to Blueprint Medicines could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Blueprint Medicines when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Blueprint Medicines - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Blueprint Medicines Corp to buy it.
The correlation of Blueprint Medicines is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Blueprint Medicines moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Blueprint Medicines Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Blueprint Medicines can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 4.118 | Quarterly Revenue Growth 0.855 | Return On Assets (0.25) | Return On Equity (1.57) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.